Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Gottlieb

Advanced Heart Failure and Transplant Cardiology Dallas, TX Medical Doctor

NPI 1386855922 CMS profile 914971

3410 Worth St, Suite 250, Dallas, TX 75246

Open in the dashboard

General payments

$717,077

664 records reported · program years 2019–2025

Research payments

$167,961

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,393,356 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Robert Gottlieb of Dallas, TX is reported in the CMS Open Payments database as having received $717,077 across 664 general payments and $167,961 in research payments paid to them. Separately, studies naming them as principal investigator received $13,393,356 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $146,316 127
2024 General $82,894 86
2023 General $219,677 142
2023 Research $26,794 5
2022 General $75,054 61
2022 Research $300 1
2021 General $93,330 43
2021 Research $2,491 3
2020 General $34,374 24
2020 Research $138,376 4
2019 General $65,432 181

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Gottlieb
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Robert Gottlieb were reported at $146,316. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Robert Gottlieb Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $65,432 $863 $224–$4,562 $163
2020 $34,374 $452 $122–$3,992 $114
2021 $93,330 $550 $159–$3,571 $132
2022 $75,054 $729 $221–$4,357 $149
2023 $219,677 $1,002 $309–$5,827 $160
2024 $82,894 $931 $273–$5,204 $164
2025 $146,316 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $404,158 446 payments
  2. Gilead Sciences, Inc. $203,879 121 payments
  3. Invivyd Inc $19,340 15 payments
  4. AbbVie, Inc. $18,400 4 payments
  5. F. Hoffmann-La Roche AG $18,085 4 payments
  6. Pfizer Inc. $10,116 5 payments
  7. Janssen Research & Development, LLC $10,000 1 payment
  8. GlaxoSmithKline, LLC. $8,450 3 payments
  9. Eli Lilly and Company $7,108 4 payments
  10. Kamada Ltd. $5,328 3 payments
  11. Other $12,214 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $385,576 112 payments
  2. Consulting Fee $199,306 51 payments
  3. Travel and Lodging $118,157 252 payments
  4. Food and Beverage $13,532 248 payments
  5. Education $507 1 payment
Products named General payments · program years 2019–2025
  1. AMVUTTRA $194,806 179 payments
  2. ONPATTRO $173,685 216 payments
  3. Veklury $91,424 57 payments
  4. PEMGARDA $16,790 14 payments
  5. VYNDAQEL $10,116 5 payments
  6. CYTOGAM $5,328 3 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $313 4 payments
  8. HeartWare HVAD $301 4 payments
  9. Epclusa $224 3 payments
  10. ULTOMIRIS $175 1 payment
  11. Other $1,561 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $137,617 2 payments
  2. F. Hoffmann-La Roche AG $21,471 3 payments
  3. Pfizer Inc. $7,670 4 payments
  4. Carmat $904 3 payments
  5. E.R. Squibb & Sons, L.L.C. $300 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

343

Median for Cardiology: 2,533

Drug cost

$48,365

Median for Cardiology: $485,213

Branded share of claims

13.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 22 $40,080
Tacrolimus Generic 13 $1,595
Bumetanide Generic 13 $1,458
Dapsone Generic 11 $947
Metoprolol Succinate Generic 34 $875
Rosuvastatin Calcium Generic 30 $647
Carvedilol Generic 45 $535
Atorvastatin Calcium Generic 24 $394
Spironolactone Generic 23 $308
Amitriptyline Hcl Generic 13 $267

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$29,014

Medicare's payments for the services billed

Medicare patients

95

Average age 68

Services billed

347

29 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Chronic kidney disease 75%
Ischemic heart disease 72%
Atrial fibrillation 59%
Diabetes 54%
Arthritis 37%
Depression 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $47,799
$47,799 — —
Veklury
  • Gilead Sciences, Inc. $25,704
$25,704 — —
CYTOGAM
  • Kamada Ltd. $5,328
$5,328 — —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $113
$113 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $58
$58 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

677 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record